[1] Tanaka S,Sugiura Y,Saito H,et al.Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney Int,2018,94(5):912-925. [2] Sao R,Aronow WS.Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci,2018,14(6):1233-1244. [3] Aronow WS.Nonalcoholic fatty liver disease is associated with coronary artery disease and subclinical atherosclerosis. Future Cardiol,2016,2(4):393-396. [4] Kurokawa T,Ohkohchi N.Platelets in liver disease,cancer and regeneration. World J Gastroenterol,2017,23(18):3228-3239. [5] Reccia I,Kumar J,Akladios C,et al.Non-alcoholic fatty liver disease:A sign of systemic disease. Metabolism,2017,72:94-108. [6] 陈灏珠,林果为,王吉耀. 实用内科学.14版. 人民卫生出版社,2013:1997-2007. [7] 徐建军,潘锋,徐虹. 中药正肝汤对乙型肝炎肝硬化患者血清瘦素、脂联素水平以及胰岛素抵抗影响的分析. 中华流行病学杂志,2015,36(4):399-401. [8] Cansancao K,Silva Monteiro L,Carvalho Leite N,et al.Advanced liver fibrosis is independently associated with palmitic acid and insulin levels in patients with non-alcoholic fatty liver disease. Nutrients,2018,10(11):1586. [9] Vulf MA,Kirienkova EV,Skuratovskaia DA,et al.Factors governing development of nonalcoholic fatty liver disease and insulin resistance in obesity. Biomed Khim,2018,64(5):444-450. [10] De Souza Mesquita LM,Caria CREP,Santos PS,et al. Modulatory effect of polyphenolic compounds from the mangrove tree rhizophora mangle L. on non-alcoholic fatty liver disease and insulin resistance in high-fat diet obese mice. Molecules,2018,23(9):2114. [11] Kessoku T,Yoneda M,Sumida Y,et al.Insulin resistance correlated with the severity of liver histology in Japanese NAFLD patients:a multicenter retrospective study. J Clin Gastroenterol,2015,49(2):169-170. [12] 胡庆玲,黄亚雄,谢元林. 肝源性糖尿病发病机制研究进展. 实用肝脏病杂志,2016,19(3):377-380. [13] Grancini V,Trombetta M,Lunati ME,et al.Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes:Role of severity of liver disease. J Hepatol,2015,63(6):1484-1490. [14] Virtue A,Johnson C,Lopez-Pastrana J,et al.MicroRNA-155 deficiency leads to decreased atherosclerosis,increased white adipose tissue obesity,and non-alcoholic fatty liver disease:A novel mouse model of obesity paradox. J Biol Chem,2017,292(4):1267-1287. [15] Simon TG,Corey KE,Chung RT,et al.Cardiovascular risk reduction in patients with nonalcoholic fatty liver disease:The potential role of ezetimibe. Dig Dis Sci,2016,61(12):3425-3435. [16] Watanabe S,Kumazaki S,Kusunoki K,et al.A high-fat and high-cholesterol diet induces cardiac fibrosis,vascular endothelial,and left ventricular diastolic dysfunction in SHRSP5/Dmcr rats. J Atheroscler Thromb,2018,25(5):439-453. [17] Fadaei R,Poustchi H,Meshkani R,et al.Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci Rep,2018,8(1):11691. [18] Fracanzani AL,Petta S,Lombardi R,et al.Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease,and association with visceral obesity. Clin Gastroenterol Hepatol,2017,15(10):1604-1611. [19] 何方平. 非酒精性脂肪性肝病与动脉粥样硬化.实用肝脏病杂志,2017,20(3):263-266. [20] Peters KM,Wilson RB,Borradaile NM.Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis. Curr Opin Lipidol,2018,29(5):417-422. [21] 侯峰,赵瑞平. 非酒精性脂肪性肝病与冠状动脉钙化相关性的研究进展. 中华心血管病杂志,2017,45(10):899-901. |